BioSpace News Archive

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees options to purchase an aggregate of 140,000 shares of BioCryst common stock on January 31, 2020 as inducements material to each employee entering into employment with BioCryst.

Specialized division focused on research and product development for rare and ultra-rare diseases highlights Chiesi’s commitment to building a brighter future for patients

Formulation will be First Nutraceutical Compound to be Introduced Under Guardion’s Recently Acquired NutriGuard Business Line

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that the Series A convertible voting preferred stock issued in its recently completed $103.0 million financing (gross proceeds) have been fully converted into shares of common stock.

Two Labs, an industry-leading pharma services company, today announced that it has acquired CEEK Enterprises, a management consultancy dedicated to supporting clients in the biopharma and MedTech industries with specialized expertise in corporate development, commercial strategy, clinical development and medical affairs.

The panel discussion moderated by Lung is at The Hyatt Regency Grand Cypress in Orlando from 4:20-5:00pm. In addition, Lung will participate as a panelist at 11:10AM on ‘Addressing Social Determinants of Health: Helping Vulnerable Populations Thrive through Community Partnerships and Targeted Interventions’

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company’s business strategy and development-stage programs will be given at the Guggenheim Healthcare Talks Idea Forum Oncology Day being held in New York.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, has joined forces with the 25-30 million Americans living with a rare disease and health care advocates around the world for Rare Disease Day® on February 29.

Feb. 6, 2020 12:00 UTC Industry Veteran Brings Deep Expertise in Leading and Scaling Commercial Operations in Medical Device Companies REDWOOD CITY, Calif.--( BUSINESS WIRE )-- PROCEPT BioRobotics Corporation , a Silicon Valley surgical robotics company developing intelligent solutions to transform the field of urology, has announced the appointment of Reza Zadno, PhD, as its new president and chief executive officer. With more than three decades of leadership experience

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced the time of its fourth quarter and fiscal year 2019 earnings release and conference call.